Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astellas Pharma Unsp/Adr (ALPMY)

Astellas Pharma Unsp/Adr (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 29,316,496
  • Shares Outstanding, K 1,809,660
  • Annual Sales, $ 12,621 M
  • Annual Income, $ 334,930 K
  • EBIT $ 996 M
  • EBITDA $ 2,488 M
  • 60-Month Beta 0.18
  • Price/Sales 2.13
  • Price/Cash Flow 8.87
  • Price/Book 2.89
  • Price/Earnings ttm 11.32
  • Earnings Per Share ttm 1.41
  • Most Recent Earnings $0.30 on 10/30/25
  • Next Earnings Date 04/24/26
  • Annual Dividend & Yield (Fwd) 0.34 (2.13%)
  • Most Recent Dividend 0.170 on 09/26/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.27
  • Growth Rate Est. (year over year) +369,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.8220 +18.04%
on 01/28/26
16.9500 -3.75%
on 02/10/26
+1.9850 (+13.85%)
since 01/23/26
3-Month
12.5000 +30.52%
on 11/28/25
16.9500 -3.75%
on 02/10/26
+3.5950 (+28.26%)
since 11/25/25
52-Week
8.3700 +94.92%
on 04/10/25
16.9500 -3.75%
on 02/10/26
+6.3850 (+64.30%)
since 02/25/25

Most Recent Stories

More News
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen1,600.00. The company’s shares closed last Friday at $11.10.Elevate Your Investing...

ALPMY : 16.3150 (+0.71%)
ALPMF : 15.6750 (-8.55%)
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025

- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -

ALPMY : 16.3150 (+0.71%)
Astellas Announces Top Management Personnel Change

TOKYO , Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the following changes to its Top Management...

ALPMY : 16.3150 (+0.71%)
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"

- Supporting Korean Startups' Drug Discovery Research and Global Expansion -

ALPMY : 16.3150 (+0.71%)
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

BAC : 51.69 (+2.54%)
ALPMY : 16.3150 (+0.71%)
APLS : 21.42 (-3.21%)
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years

The multibillionaire's portfolio features some moneymaking ideas.

MSFT : 400.60 (+2.98%)
GOOG : 313.03 (+0.68%)
GOOGL : 312.90 (+0.64%)
ALPMY : 16.3150 (+0.71%)
AMZN : 210.64 (+1.00%)
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

XPH : 58.41 (+0.65%)
XLV : 157.83 (-0.03%)
HZNP : 116.30 (+0.04%)
NVO : 38.16 (-1.11%)
ALPMY : 16.3150 (+0.71%)
JNJ : 245.17 (-0.45%)
MRK : 122.46 (-1.19%)
LLY : 1,028.83 (-1.28%)
NVS : 166.85 (-0.16%)
AMGN : 384.33 (+0.38%)
BMY : 61.30 (-0.49%)
Why Shares of Annexon Are Plummeting Thursday

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

ALPMY : 16.3150 (+0.71%)
ISEE : 39.95 (+0.38%)
APLS : 21.42 (-3.21%)
ANNX : 5.09 (+2.62%)
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today.

TGTX : 29.66 (-2.79%)
VKTX : 33.12 (-1.87%)
ALPMY : 16.3150 (+0.71%)
APLS : 21.42 (-3.21%)
ISEE : 39.95 (+0.38%)
Pfizer buys Seagen for $43B, boosts access to cancer drugs

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue

ALPMY : 16.3150 (+0.71%)
$SPX : 6,946.13 (+0.81%)
$DOWI : 49,482.15 (+0.63%)
$IUXX : 25,329.04 (+1.41%)
PFE : 27.09 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment...

See More

Key Turning Points

3rd Resistance Point 17.1712
2nd Resistance Point 16.7606
1st Resistance Point 16.5378
Last Price 16.3150
1st Support Level 15.9044
2nd Support Level 15.4938
3rd Support Level 15.2710

See More

52-Week High 16.9500
Last Price 16.3150
Fibonacci 61.8% 13.6724
Fibonacci 50% 12.6600
Fibonacci 38.2% 11.6476
52-Week Low 8.3700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar